HRP20171651T1 - (s)-pirlindol i njegove farmaceutski prihvatljive soli za uporabu u medicini - Google Patents
(s)-pirlindol i njegove farmaceutski prihvatljive soli za uporabu u medicini Download PDFInfo
- Publication number
- HRP20171651T1 HRP20171651T1 HRP20171651TT HRP20171651T HRP20171651T1 HR P20171651 T1 HRP20171651 T1 HR P20171651T1 HR P20171651T T HRP20171651T T HR P20171651TT HR P20171651 T HRP20171651 T HR P20171651T HR P20171651 T1 HRP20171651 T1 HR P20171651T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrlindole
- pharmaceutically acceptable
- enantiomer
- acceptable salt
- use according
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 12
- 229950002220 pirlindole Drugs 0.000 title claims 5
- 239000003814 drug Substances 0.000 title 1
- -1 glucomethacin Chemical compound 0.000 claims 6
- 239000000730 antalgic agent Substances 0.000 claims 4
- 238000002648 combination therapy Methods 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 claims 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 claims 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 claims 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 229960004420 aceclofenac Drugs 0.000 claims 1
- 229960004892 acemetacin Drugs 0.000 claims 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 229960001671 azapropazone Drugs 0.000 claims 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims 1
- 229960005430 benoxaprofen Drugs 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- CVNFYQCHAWFYQI-ZSCHJXSPSA-N clonixin lysine salt Chemical compound NCCCC[C@H](N)C(O)=O.CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CVNFYQCHAWFYQI-ZSCHJXSPSA-N 0.000 claims 1
- 108700023159 delta Opioid Receptors Proteins 0.000 claims 1
- 102000048124 delta Opioid Receptors Human genes 0.000 claims 1
- 229960003428 dexibuprofen Drugs 0.000 claims 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims 1
- 229960002783 dexketoprofen Drugs 0.000 claims 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 229960004590 diacerein Drugs 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229960004028 eslicarbazepine Drugs 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960001493 etofenamate Drugs 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 229960001395 fenbufen Drugs 0.000 claims 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 229960002679 fentiazac Drugs 0.000 claims 1
- 229960000489 feprazone Drugs 0.000 claims 1
- 229960004369 flufenamic acid Drugs 0.000 claims 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960004187 indoprofen Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000001057 ionotropic effect Effects 0.000 claims 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960003763 lysine clonixinate Drugs 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 229960003251 morniflumate Drugs 0.000 claims 1
- LDXSPUSKBDTEKA-UHFFFAOYSA-N morniflumate Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OCCN2CCOCC2)=C1 LDXSPUSKBDTEKA-UHFFFAOYSA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 229960000916 niflumic acid Drugs 0.000 claims 1
- 229960000965 nimesulide Drugs 0.000 claims 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960004534 orgotein Drugs 0.000 claims 1
- 108010070915 orgotein Proteins 0.000 claims 1
- AJRNYCDWNITGHF-UHFFFAOYSA-N oxametacin Chemical compound CC1=C(CC(=O)NO)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AJRNYCDWNITGHF-UHFFFAOYSA-N 0.000 claims 1
- 229960002739 oxaprozin Drugs 0.000 claims 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960003676 tenidap Drugs 0.000 claims 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims 1
- 229960002871 tenoxicam Drugs 0.000 claims 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960001312 tiaprofenic acid Drugs 0.000 claims 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002905 tolfenamic acid Drugs 0.000 claims 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 229960003414 zomepirac Drugs 0.000 claims 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 claims 1
- 108020001588 κ-opioid receptors Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol za terapiju ili prevenciju neuropatske boli.
2. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol za uporabu prema patentnom zahtjevu 1, naznačeni time da je (S)-pirlindol enantiomerno čist.
3. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol za uporabu prema patentnim zahtjevima 1 i 2, u kombiniranoj terapiji s najmanje jednim dodatnim analgetskim sredstvom.
4. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol, namjenjen upotrebi prema patentnom zahtjevu 3, gdje kombinirana terapija uključuje kombiniranu terapiju s fiksnom dozom ili posebnu kombiniranu terapiju odabranu iz sekvencijalne ili istovremene primjene aktivnih sredstava.
5. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol, najmenjen upotrebi prema patentnim zahtjevima 3 i 4 za potenciranje učinaka najmanje jednog dodatnog analgetskog sredstva za liječenje neuropatske boli.
6. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol namjenjen upotrebi prema bilo kojem od patentnih zahtjeva 1 do 5 u obliku (S)-pirlindol (R)-mandelat soli.
7. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol namjenjen upotrebi prema bilo kojem od patentnih zahtjeva 1 do 5, u obliku (S)-pirlindol mezilat soli.
8. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sola namjenjen upotrebi prema bilo kojem od patentnih zahtjeva 1 do 5, u obliku (S)-pirlindol citrat soli.
9. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol namjenjen upotrebi prema patentnim zahtjevima 3 do 8, naznačeni time da je najmanje jedno dodatno analgetsko sredstvo spoj koji smanjuje neuronsku hiperosjetljivost odabrano iz skupine koju čine: inhibitori natrijevih kanala, kao što su karbamazepin, okskarbazepin, eslikarbazepin, fenitoin i valproična kiselina; antagonisti kalcijevih kanala, kao što su pregabalin; ionotropni i metabotropni antagonisti receptora glutamata; pojačivači aktivnosti γ-aminobutirne kiseline, kao što je gabapentin; ili agonisti djelomični agonisti/antagonisti ili antagonisti m, κ, i δ opioidnih receptora.
10. (S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol namjenjen upotrebi prema patentnim zahtjevima 3 do 8, naznačeni time da najmanje jedno dodatno analgetsko sredstvo je spoj odabrano iz skupine koju čine: paracetamol, glukozamin, diacerein ili nesteroidni anti-inflamatorni lijek, kao što je acetilsalicilna kiselina, diklofenak, nabumeton, nimesulid, nabumeton, etodolak, piroksikam, lizin kloniksinat, diflunisal, acemetacin, glukametacin, indometacin, proglumetacin, oksametacin, sulindak, aceklofenak, fentiazak, ketorolak, zomepirak, meloksikam, tenoksikam, lornoksikan, fenoprofen, fenbufeno, flurbiprofen, benoksaprofen, ibuprofen, ketoprofen, deksketoprofen, pirprofen, indoprofen, naproksen, oksaprozin, tiaprofen, deksibuprofen, meklofenamnska kiselina, mefenaminska kiselina, flufenaminska kiselina, tolfenaminska kiselina, nifluminska kiselina, etofenamat, azapropazon, orgotein, feprazon, morniflumat, tenidap, glikozaminoglikan, polisulfat, celekoksib, rofekoksib, parekoksib, valdekoksib, i etorikoksib.
11. Farmaceutski pripravak namjenjen liječenju neuropatske boli koja sadrži (S)-pirlindol enantiomer ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od prethodnih patentnih zahtjeva zajedno s farmaceutski prihvatljivim nosačima, vehikulumima ili ekscipijentime.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14726444.4A EP3057589B1 (en) | 2014-05-09 | 2014-05-09 | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine |
PCT/PT2014/000029 WO2015171005A1 (en) | 2014-05-09 | 2014-05-09 | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171651T1 true HRP20171651T1 (hr) | 2017-12-15 |
Family
ID=50819931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171651TT HRP20171651T1 (hr) | 2014-05-09 | 2017-10-30 | (s)-pirlindol i njegove farmaceutski prihvatljive soli za uporabu u medicini |
Country Status (29)
Country | Link |
---|---|
US (1) | US9814712B2 (hr) |
EP (1) | EP3057589B1 (hr) |
JP (1) | JP6768520B2 (hr) |
KR (1) | KR102298676B1 (hr) |
CN (1) | CN106456637B (hr) |
AU (1) | AU2014393490B2 (hr) |
CA (1) | CA2948598C (hr) |
CY (1) | CY1119532T1 (hr) |
DK (1) | DK3057589T3 (hr) |
EC (1) | ECSP16086247A (hr) |
ES (1) | ES2649492T3 (hr) |
HR (1) | HRP20171651T1 (hr) |
HU (1) | HUE035071T2 (hr) |
IL (1) | IL248855B (hr) |
LT (1) | LT3057589T (hr) |
MA (1) | MA39447B1 (hr) |
MX (1) | MX368734B (hr) |
NO (1) | NO3057589T3 (hr) |
NZ (1) | NZ726132A (hr) |
PH (1) | PH12016502233A1 (hr) |
PL (1) | PL3057589T3 (hr) |
PT (1) | PT3057589T (hr) |
RS (1) | RS56591B1 (hr) |
RU (1) | RU2695647C2 (hr) |
SA (1) | SA516380264B1 (hr) |
SI (1) | SI3057589T1 (hr) |
TN (1) | TN2016000498A1 (hr) |
UA (1) | UA118474C2 (hr) |
WO (1) | WO2015171005A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106413713B (zh) * | 2014-05-09 | 2020-07-14 | 特克尼梅德医疗技术股份公司 | 用作药物的吡吲哚对映异构体的药学上可接受的盐 |
RS56590B1 (sr) * | 2014-05-09 | 2018-02-28 | Tecnimede Sociedade Tecnico Medicinal S A | (r)-pirlindol i njegove farmaceutski prihvatljive soli za upotrebu u medicini |
EP3392251A1 (en) | 2017-04-21 | 2018-10-24 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Process for the preparation of pirlindole enantiomers and its salts |
EP3392250A1 (en) * | 2017-04-21 | 2018-10-24 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives |
MX2018011142A (es) | 2018-09-13 | 2019-10-10 | Federico Amezcua Amezcua | Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona. |
EP3900716A1 (en) * | 2020-04-21 | 2021-10-27 | Dompe' Farmaceutici S.P.A. | Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2500662A1 (en) * | 2002-10-03 | 2004-04-15 | Cypress Bioscience, Inc. | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
US20060135403A1 (en) * | 2002-12-24 | 2006-06-22 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
WO2005025550A1 (en) * | 2003-09-15 | 2005-03-24 | Vectura Limited | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
CN106413713B (zh) * | 2014-05-09 | 2020-07-14 | 特克尼梅德医疗技术股份公司 | 用作药物的吡吲哚对映异构体的药学上可接受的盐 |
-
2014
- 2014-05-09 MA MA39447A patent/MA39447B1/fr unknown
- 2014-05-09 AU AU2014393490A patent/AU2014393490B2/en active Active
- 2014-05-09 CA CA2948598A patent/CA2948598C/en active Active
- 2014-05-09 ES ES14726444.4T patent/ES2649492T3/es active Active
- 2014-05-09 WO PCT/PT2014/000029 patent/WO2015171005A1/en active Application Filing
- 2014-05-09 RS RS20171094A patent/RS56591B1/sr unknown
- 2014-05-09 JP JP2016567545A patent/JP6768520B2/ja active Active
- 2014-05-09 US US15/309,899 patent/US9814712B2/en active Active
- 2014-05-09 NO NO14726444A patent/NO3057589T3/no unknown
- 2014-05-09 TN TN2016000498A patent/TN2016000498A1/en unknown
- 2014-05-09 EP EP14726444.4A patent/EP3057589B1/en active Active
- 2014-05-09 PT PT147264444T patent/PT3057589T/pt unknown
- 2014-05-09 MX MX2016014699A patent/MX368734B/es active IP Right Grant
- 2014-05-09 UA UAA201611332A patent/UA118474C2/uk unknown
- 2014-05-09 KR KR1020167031373A patent/KR102298676B1/ko active IP Right Grant
- 2014-05-09 HU HUE14726444A patent/HUE035071T2/en unknown
- 2014-05-09 LT LTEP14726444.4T patent/LT3057589T/lt unknown
- 2014-05-09 RU RU2016148183A patent/RU2695647C2/ru active
- 2014-05-09 NZ NZ726132A patent/NZ726132A/en unknown
- 2014-05-09 SI SI201430462T patent/SI3057589T1/sl unknown
- 2014-05-09 DK DK14726444.4T patent/DK3057589T3/da active
- 2014-05-09 PL PL14726444T patent/PL3057589T3/pl unknown
- 2014-05-09 CN CN201480078727.XA patent/CN106456637B/zh active Active
-
2016
- 2016-11-09 EC ECIEPI201686247A patent/ECSP16086247A/es unknown
- 2016-11-09 SA SA516380264A patent/SA516380264B1/ar unknown
- 2016-11-09 PH PH12016502233A patent/PH12016502233A1/en unknown
- 2016-11-09 IL IL248855A patent/IL248855B/en active IP Right Grant
-
2017
- 2017-10-30 CY CY20171101123T patent/CY1119532T1/el unknown
- 2017-10-30 HR HRP20171651TT patent/HRP20171651T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171651T1 (hr) | (s)-pirlindol i njegove farmaceutski prihvatljive soli za uporabu u medicini | |
HRP20171650T1 (hr) | (r)-pirlindol i njegove farmaceutski prihvatljive soli za uporabu u medicini | |
HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
BR112014016085A8 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
RU2015134142A (ru) | Композиции твердых растворов и их применение при сильной боли | |
MX2018001584A (es) | Composiciones de solución sólida para aines. | |
CA2570503A1 (en) | A method of improving the medical treatment of pain | |
JP2019521116A5 (hr) | ||
JP2017536421A5 (hr) | ||
NZ602029A (en) | Use of meloxicam for the long-term treatment of kidney disorders in cats | |
BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
MX2014013148A (es) | Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexano-1,1´-pirano-[3,4, b]indol]-4-amina y un derivado de acido propionico. | |
BR112015025058A2 (pt) | composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma | |
HRP20131070T1 (hr) | Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima | |
RU2015115398A (ru) | N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении | |
CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
RU2015112586A (ru) | Фармацевтические композиции, содержащие флурбипрофен | |
BR112018068155A2 (pt) | composição farmacêutica de liberação prolongada que compreende cisteamina ou sais da mesma | |
AR063228A1 (es) | Antinflamatorios no esteroideos contra la tos | |
RU2012102980A (ru) | Лекарственное средство для длительного применения nsaid | |
RU2015100897A (ru) | Композиция для предупреждения или лечения колита, содержащая s-аллил-l-цистеин в качестве активного ингредиента, и содержащий ее медицинский препарат | |
RU2017113827A (ru) | Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения | |
PE20170136A1 (es) | Combinacion de un aine y un aminoacido | |
SI2849747T1 (en) | A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano , 4, b) indol) -4-amine and NSAID |